Targeted Therapy for Melanomas Without BRAF V600 Mutation

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) have transformed metastatic melanoma treatment.
• A significant need exists for alternative therapies in patients intolerant or refractory to immunotherapy.
• Focus is on BRAF wild-type melanoma, a subset requiring distinct treatment strategies.

Purpose of the Study:

• To review the role and clinical efficacy of targeted therapies in BRAF wild-type melanoma.
• To explore emerging therapeutic strategies beyond traditional immunotherapy.

Main Methods:

• Review of genomic analyses identifying driver mutations in BRAF wild-type melanoma.
• Evaluation of targeted therapies, including small molecule inhibitors, bispecific antibodies, and antibody drug conjugates.
• Assessment of clinical efficacy data for various targeted agents.

Main Results:

• Genomic studies reveal targetable mutations in MAPK and PI3K-AKT pathways in BRAF wild-type melanoma.
• Novel agents like bispecific antibodies and antibody drug conjugates show potential clinical activity, even in rare subtypes.
• Molecular-targeted therapies have shown modest success but hold promise for select patient groups with distinct genetic profiles.

Conclusions:

• Targeted therapies represent a valuable, albeit selective, treatment avenue for BRAF wild-type melanoma.
• Next-generation immunotherapies and immunomodulators are emerging as significant advancements.
• Further research is crucial for identifying new targets and combination strategies to improve outcomes.